Exophthalmos

New York, NY, April 04, 2024 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (Lirum), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the upcoming presentation of positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held from April 5-10 in San Diego, California. Lirum’s data covers clinically-tested LX-101’s potent preclinical anti-tumor activity against variety of adult and pediatric cancers, including cancers of the head and neck and breast as well as certain sarcomas and neuroblastoma, all of which have well-established IGF-1R pathway involvement. In particular, these malignancies have known genetic alterations affecting the IGF-1R pathway and/or high IGF-1R expression tied to poor outcomes. The poster (abstract 1918) will be presented on Monday April 8th from 9:00am to 12:30pm PT in Section 23 of the poster hall and will also be available on the Lirum website (www.lirumtx.com) at the time of its presentation under the Investors and Media tab. Given these promising results and the existing clinical data, Lirum is planning new clinical trials with LX-101 focused on oncologic indications, both pediatric and adult, that carry well-established ties to the IGF-1/IGF-1R pathway. Lirum is also developing LX-101 in certain autoimmune diseases, including thyroid dye disease, where IGF-1R has been clinically and commercially validated. About Lirum Therapeutics, Inc.Lirum is an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways and commercial opportunities. Lirum’s lead candidate, LX-101, is a novel clinical-stage targeted therapy directed to the insulin-like growth factor-1 receptor (IGF-1R) with a differentiated mechanism of action. Lirum is developing LX-101 in oncology and autoimmune indications, including thyroid eye disease (TED). For more information on Lirum, please visit www.lirumtx.com. Forward Looking StatementsThis press release contains certain “forward-looking statements” within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements can be identified by words such as: aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others: our ability to successfully develop our product candidates, including obtaining positive results from planned clinical trials; expectations for the clinical development, manufacturing, regulatory approval and commercialization of our product candidates or other products we may acquire or in-license; expectations for incurring capital expenditures and generating revenue; estimates of the sufficiency of our existing cash and cash equivalents and investments to finance operations; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; the impact of health epidemics, including the COVID-19 pandemic, on our business and the actions we may take in response thereto; and other risks and uncertainties indicated from time to time. Although we believe that the plans and expectations reflected in any forward-looking statements are based on reasonable assumptions, we can give no assurance that our plans and expectations will be attained, and therefore actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including those identified elsewhere in this communication and those included in the “Risk Factors” section in our most recently filed Registration Statement on Form S-1 and in other documents that we may file with the SEC, which are available at https://www.sec.gov. These cautionary statements qualify all of our forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements. Our forward-looking statements speak only as of the date they are made and should not be relied upon as representing our plans and expectations as of any subsequent date. While we may elect to update or revise forward-looking statements at some time in the future, we specifically disclaim any obligation to publicly release the results of any revisions to our forward-looking statements, except as required by law. Company contact: Matt HobermanInvestor RelationsIR@lirumtx.com Phone: (646) 389-6015 Lirum Therapeutics, Inc.590 Madison Avenue 21st FloorNew York, NY 10022

WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 102,000 shares of the company’s common stock to three new employees (the “Inducement Grants”) on April 1, 2024 (the “Grant Date”). The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to each employee’s continued employment with Viridian through the applicable vesting dates. About Viridian Therapeutics Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Viridian is based in Waltham, Massachusetts. For more information, please visit . Follow Viridian on LinkedIn and X. View source version on businesswire.com: Contacts Louisa Stone, 617-272-4604 Manager, Investor Relations IR@viridiantherapeutics.com Source: Viridian Therapeutics, Inc. View this news release online at:

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA. Glaukos will be exhibiting onsite at booth #631. In addition, Glaukos is sponsoring an educational symposium in conjunction with ASCRS and EyeWorld entitled, “The Catalysts to Advance the Interventional Glaucoma Revolution: iDose® TR (travoprost intracameral implant) 75 mcg and iStent infinite®” on Friday, April 5, 2024, at 12:00-1:00 p.m. ET in Room 252AB at the Boston Convention & Exhibition Center. The faculty includes Ike Ahmed, MD (Moderator); Sahar Bedrood, MD; John Berdahl, MD; Manjool Shah, MD; and Blake Williamson, MD. Go here for more information and to register. Key Glaucoma Presentations: Saturday, April 6, 2024 10:28-10:33 a.m., I. Paul Singh, MD Efficacy of Travoprost Intraocular Implant in Diverse Subpopulations of Patients with Open-Angle Glaucoma or Ocular Hypertension 10:33-10:38 a.m., Christy Benson, MD Early Outcomes After Third-Generation Trabecular Micro-Bypass with/without Goniotomy in Eyes with Failed Prior Glaucoma Intervention 10:33-10:38 a.m., Cristos Ifantides, MD, MBA Two-Year Comparison of 2 Trabecular MIGS Devices in Patients with Mild to Severe Open-Angle Glaucoma 10:38-10:43 a.m., Steven Sarkisian, MD Standalone Procedure of Administration of Travoprost Intraocular Implant is Safe and Effective in Phakic Eyes 10:43-10:48 a.m., Rom Kandavel, MD 12-Month Efficacy Results of Trabecular Micro-Bypass in Patients Stratified by Prior Laser or Incisional Glaucoma Surgery 10:51-10:56 a.m., John Berdahl, MD Travoprost Intraocular Implant in Eyes with Prior Selective or MicroPulse Laser Trabeculoplasty Sunday, April 7, 2024 8:50-8:55 a.m., Ali Salimi, MD A Decade-Long Outcomes of Two First-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in Primary Open-Angle Glaucoma 9:05-9:10 a.m., Mitchell Schultz, MD Preliminary Outcomes of 3 Microstents as Trabecular MIGS Device with or without Canaloplasty in Mild and Moderate Open-Angle Glaucoma Key Glaucoma Posters: Jason Bacharach, MD Travoprost Intraocular Implant: Analysis of Topical Prostaglandin Analog-associated Adverse Events Fritz Hengerer, MD 7-Year Outcomes after Second-Generation Trabecular Micro-Bypass in Eyes with or without Prior Glaucoma Surgery Brittany Long Comparison of Two Different MIGS Devices with Combined Canaloplasty in Moderate Glaucoma at the Time of Cataract Surgery Deborah Ristvedt, DO Third-Generation Trabecular Micro-Bypass in Eyes Failing Prior Surgical and/or Medical Glaucoma Therapy Valerie Trubnik, MD Usage of Three Trabecular Mico-Bypass Stents Combined with Phacoemulsification in Surgically Naïve Glaucoma Patients Zachary Vest, MD Early Outcomes After Third-Generation Trabecular Micro-Bypass Performed with Phacoemulsification in Patients with Open-Angle Glaucoma Edward Yung, MD Outcomes after Viscoelastic Delivery in Patients with Glaucoma Key Corneal Health Presentations: Friday, April 5, 2024 9:13-9:21 a.m., Michael Raizman, MD Cross-Linking – Now and What’s Coming Saturday, April 6, 2024 3:31-3:41 p.m., Brandon Ayres, MD Keratoconus – Surgical Innovations Sunday, April 7, 2024 10:00-10:05 a.m., Kenneth Beckman, MD Safety of a Scanning Laser-based Bioactivation System for Corneal Cross-Linking in Keratoconus Abstract information can be found at . The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry. All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve or recommend the use of any products, devices or services. About Glaukos Glaukos ( ) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases. About iDose® TR (U.S.) iDose TR (travoprost intracameral implant) is a long duration prostaglandin analog approved for a single administration and indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Made from medical-grade titanium, iDose TR is implanted through the trabecular meshwork and back wall of Schlemm's canal, directly into scleral tissue. Once implanted, 75 mcg of a novel, preservative-free, proprietary formulation of travoprost continuously elutes into the anterior chamber via membrane-controlled diffusion, allowing for 24/7 release of medication. Indication for Use: iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). Dosage and Administration: For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions. Contraindications: iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product. Warnings and Precautions: iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent. Adverse Reactions: In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity. About iStent infinite® Trabecular Micro-Bypass System (U.S.) Indication for Use: The iStent infinite Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed. Contraindications: The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. Warnings: Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard. MRI Information: The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details. Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic. Adverse Events: The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%). Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events. For more information, visit . Forward-Looking Statements All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the timing and extent to which obtain regulatory approval for investigational products, our ability to successfully commercialize such products, the ability to obtain and maintain adequate financial coverage and reimbursement for our products, and the continued efficacy and safety pro our products as might be suggested in the presentations at the ASCRS meeting. These and other risks, uncertainties and factors related to Glaukos, and our business are described in detail under the caption “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (SEC) on February 23, 2024. Our filings with the SEC are available in the Investor Section of our website at or at . In addition, information about the risks and benefits of our products is available on our website at . All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.